Dendrimers News RSS Feed - Dendrimers

ProLynx Obtains US Patent 8,703,907 Covering Controlled Drug Release from Dendrimer Conjugates

ProLynx Obtains US Patent 8,703,907 Covering Controlled Drug Release from Dendrimer Conjugates

ProLynx LLC, a biotechnology company focused on development of disruptive drug delivery systems for half-life extension of injectable drugs today announced that the United States Patent and Trademark Office has issued US Patent 8,703,907 covering controlled release of drugs from dendrimer conjugates over prolonged periods. [More]

Nanoscale Plasma Processing Seminars - co-hosted by Oxford Instruments and Cornell University

Leader in the manufacture of plasma etch and deposition systems, Oxford Instruments is continuing its successful programme of Seminars with ‘Nanoscale Plasma Processing’ at Cornell University, Ithaca, USA ... [More]

RUSNANOPRIZE Nomination Process Reveals Great Emerging Technologies in Russia

Nanotechnological Society of Russia is involved in the process of attracting strong potential applicants for the RUSNANOPRIZE Award 2013. It occurred to be a good possibility to meet break-through industrial technolog... [More]
Makhteshim Agan and Starpharma Collaboration Presents Commercial Opportunity for Priostar Dendrimers

Makhteshim Agan and Starpharma Collaboration Presents Commercial Opportunity for Priostar Dendrimers

Starpharma Holdings Ltd and Makhteshim Agan Group today announced a collaboration program. This will see Starpharma's Priostar® dendrimer technology applied to novel crop protection formulations across Makhteshim Agan's extensive product portfolio. [More]
Evolution of Dendrites to be Studied in the Absence of Gravity

Evolution of Dendrites to be Studied in the Absence of Gravity

Northwestern University research has a wide reach. This month, it went all the way to outer space. [More]
NJIT Honors Inventor of Living Cell Nanoprobe

NJIT Honors Inventor of Living Cell Nanoprobe

NJIT Research Professor Reginald C. Farrow, PhD, who with his research team have discovered how to make nanoscale arrays of the world's smallest probe for investigating the electrical properties of individual living, cells will receive on Oct. 4, 2012 the NJIT Board of Overseers Excellence in Research Prize and Medal. Larger electrical probes have been extremely important in understanding these properties, as indicated by the Nobel Prizes awarded to the inventors of two previous generations of probes. [More]
Dendrimer-Fullerenol Nanoassembly for Drug Delivery and Environmental Remediation Applications

Dendrimer-Fullerenol Nanoassembly for Drug Delivery and Environmental Remediation Applications

In a paper, ‘Dendrimer-fullerenol soft-condensed nanoassembly,’ reported in The Journal of Physical Chemistry C, researchers from Clemson University and their collaborators have demonstrated the way of using dendrimer, a soft nanomaterial, to protect the environment against potentially toxic nanomaterials. [More]
Comprehensive Book on Dendrimer-Based Drug Delivery Systems

Comprehensive Book on Dendrimer-Based Drug Delivery Systems

Research and Markets has included a new book titled ‘Dendrimer-Based Drug Delivery Systems. From Theory to Practice’ to its catalogue. [More]
Genisphere’s 3DNA Dendrimer Technology Adapted for Lateral Flow Point-of-Care Assays

Genisphere’s 3DNA Dendrimer Technology Adapted for Lateral Flow Point-of-Care Assays

Genisphere has announced the adaption of its breakthrough 3DNA dendrimer signal amplification technology for use in lateral flow (LF) point-of-care (POC) assays, delivering enhanced sensitivity and facilitating a variety of new POC tests. [More]
Researchers Develop Novel Dendrimer Drug Delivery System to Treat Incurable Retinal Diseases

Researchers Develop Novel Dendrimer Drug Delivery System to Treat Incurable Retinal Diseases

Researchers at Mayo Clinic, Johns Hopkins Medicine and Wayne State University have demonstrated a novel sustained-release drug delivery system wherein dendrimers allow the delivery of steroids into the targeted cells causing damage through neuroinflammation, a major cause of retinitis pigmentosa and dry age-associated macular degeneration, thus paving the way to treat these incurable diseases. [More]